Providence First Trust’s Novo Nordisk NVO Stock Holding History

Providence First Trust’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400	Closed	-$20K	–	121
2022 Q3	$20K	Buy	+400	New	+$21.4K	0.01%	126

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Providence First Trust's NVO Position: Q4 2022 in Review

Providence First Trust sold out of Novo Nordisk (NVO) in Q4 2022, closing a stake of 400 shares — an estimated $20K sold.

Providence First Trust first reported a position in NVO in Q3 2022 and held it in 1 quarter. The position peaked at $20K in Q3 2022. 1,049 funds tracked by Wall St. Rank hold NVO as of Q4 2022.

Providence First Trust reported no remaining Novo Nordisk position as of Q4 2022 after selling out during the quarter.
Providence First Trust sold 400 Novo Nordisk shares in Q4 2022, an estimated $20K.
Providence First Trust first reported a position in Novo Nordisk in Q3 2022 and held it in 1 quarter.
Providence First Trust's Novo Nordisk position peaked at $20K in Q3 2022.
1,049 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2022.

Based on Providence First Trust's 13F filing for Q4 2022, filed 13 Feb 2023.